Introduction: Choosing between different non-vitamin K antagonist oral anticoagulants
(NOACs) in non-valvular atrial fibrillation (NVAF) is difficult due to the absence of head to …

Aim: To compare real-world effectiveness/safety of non-vitamin K antagonist oral
anticoagulants and vitamin K antagonists among patients with non-valvular atrial fibrillation …

Background Stroke is the most serious clinical consequence of atrial fibrillation, which is the
most common cardiac arrhythmia. Non-vitamin K antagonist oral anticoagulants (NOACs) …

Objectives. We conducted a systematic review and network meta-analysis of randomized
controlled trials (RCTs) including the comparison of non-vitamin K antagonist oral …

The non–vitamin K antagonist oral anticoagulants (NOACs), such as the thrombin inhibitor
(dabigatran) and the direct factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban), have …

Background: In randomized controlled trials (RCTs) direct acting oral anticoagulants
(DOACs) showed a superior risk-benefit profile in comparison to vitamin K antagonists …

Aims The well-known limitations of vitamin K antagonists (VKA) led to development of new
oral anticoagulants (NOAC) in non-valvular atrial fibrillation (NVAF). The aim of this meta …

Background. New oral anticoagulants (NOAC; rivaroxaban, dabigatran, apixaban) have
become available as an alternative to warfarin anticoagulation in non‐valvular atrial …

Purpose The nonvitamin K antagonist oral anticoagulants (NOACs) dabigatran, rivaroxaban,
apixaban, and edoxaban are used for the reduction of the risk of stroke or systemic …

Introduction: Numerous real-world studies have compared non-vitamin K antagonist oral
anticoagulants (NOACs) with vitamin K antagonists (VKAs) in patients with non-valvular …